Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
Sncg
REST API REST API
Rattus norvegicus
Sncg is differentially expressed in 74 experiments: 58 organism parts: hippocampus, ventral tegmental area, ... (56 more);, 6 disease states: normal, BDL 7 days, ... (4 more);, 9 cell types 2 cell lines 6 compound treatments and 15 other conditions.
Orthologs sncga (Danio rerio)   Q9I9H0_CHICK (Gallus gallus)   SNCG (Homo sapiens)   Sncg (Mus musculus)   sncgb (Danio rerio)   sncg (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytoskeleton, axon, cytoplasm, adult locomotory behavior, spindle, microtubule organizing center, axon terminus, perinuclear region of cytoplasm, peripheral nervous system development, regulation of neurotransmitter secretion, neuronal cell body, regulation of dopamine secretion
InterPro Term Synuclein, Synuclein_gamma
UniProt Accession Q63544, F1LQ96, D4ACB0
Search EB-eye ENSRNOG00000010437
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-3309, E-AFMX-7, E-GEOD-464, E-GEOD-3016, E-GEOD-16981, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-20037

Factor Value U/D Experiments
Rat-1 fibroblast cell line TGR
1
E-GEOD-20037
Rat-1 fibroblast cell line 15.19
1
E-GEOD-20037


Cell type

studied in E-GEOD-5940, E-GEOD-1139, E-GEOD-2499, E-TABM-130

Factor Value U/D Experiments
spermatogonium
1
E-TABM-130
bulk neural progenitor cell
1
E-GEOD-2499
fast invading C6 glial cell
1
E-GEOD-1139
astrocyte
1
E-GEOD-2499
neuron
1
E-GEOD-2499
oligodendrocyte
1
E-GEOD-5940
3 more value(s).


Disease state

studied in E-GEOD-1872, E-MEXP-1025, E-MTAB-104, E-MEXP-2583

Factor Value U/D Experiments
Sham
1
E-MEXP-2583
experimental autoimmune encephalomyelitis (acute)
1
E-MEXP-1025
BDL 7 days
1
E-MEXP-2583
bladder carcinoma
1
E-MTAB-104
breast carcinoma
1
E-GEOD-1872
normal
25
2
E-GEOD-1872, E-MTAB-104


Compound treatment

studied in E-GEOD-5509, E-GEOD-2331, E-GEOD-6119

Factor Value U/D Experiments
interleukin 1 beta and glucosamine
1
E-GEOD-6119
dimethylnitrosamine
1
E-GEOD-5509
interleukin 1 beta
1
1
E-GEOD-6119
LG100268
1
E-GEOD-2331
none
45
1
E-GEOD-2331
control
9
1
E-GEOD-6119


Clinical treatment

studied in E-GEOD-7002, E-GEOD-1616, E-MTAB-104

Factor Value U/D Experiments
inhalation
1
E-GEOD-7002
implanted tumor
1
E-MTAB-104
trigger of ischemic preconditioning
1
E-GEOD-1616
no implantation
1
E-MTAB-104
instillation
1
E-GEOD-7002


compound_treatment_design
studied in E-TABM-12

Day
studied in E-GEOD-20659

Developmental stage
studied in E-GEOD-903

Genetic modification
studied in E-GEOD-6428

Genotype
studied in E-GEOD-20037, E-GEOD-20214

Growth condition
studied in E-GEOD-6102, E-MEXP-532

Material type
studied in E-GEOD-4192

Phenotype
studied in E-MIMR-541, E-GEOD-2275

protocol
studied in E-GEOD-20895

Protocol type
studied in E-GEOD-1139, E-MEXP-1565

Replicate
studied in E-GEOD-4192

Strain or line
studied in E-MEXP-671, E-MTAB-322, E-TABM-457, E-TABM-418, E-GEOD-2116, ... (7 experiments)

tissue region
studied in E-GEOD-21681

Treatment
studied in E-GEOD-16981, E-GEOD-19909, E-GEOD-22531

Processing time: 1.032 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM